The primary objective of the study is to test the hypothesis that lung hyperinflation
contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with
FF/VI Inhalation Powder 100/25 mcg administered once daily (QD) will result in the reversal
of this cardiac dysfunction compared with placebo. This will be assessed by measures of right
and left global and regional systolic and diastolic cardiac function as assessed using a 30
minute CMR.
A secondary objective will be to investigate the effect of FF/VI inhalation powder 100/25mcg
QD on measures of arterial stiffness in the form of pulse wave analysis and distensability in
the pulmonary and systemic circulation.